Verve Therapeutics, Inc. (VERV)

Verve Therapeutics, Inc. (VERV) Healthcare & Pipeline Overview

Verve Therapeutics, Inc. is a biotechnology firm pioneering single-course gene-editing therapies for cardiovascular diseases, focusing on irreversible inactivation of genes like PCSK9 and ANGPTL3 to durably lower blood lipids. Leveraging strategic partnerships and proprietary technology, the company aims to transform treatment paradigms for chronic heart conditions.

What Is the Investment Thesis for VERV?

Verve Therapeutics, Inc. presents an investment thesis centered on its pioneering gene-editing platform addressing cardiovascular diseases, a market with substantial unmet needs. The company's primary focus on single-course therapies, like VERVE-101 targeting the PCSK9 gene and its ANGPTL3 program, aims to offer durable lipid-lowering solutions, potentially disrupting existing treatment paradigms. This innovative approach, backed by strategic partnerships with Beam Therapeutics and Acuitas Therapeutics, provides a strong technological foundation and access to critical delivery systems. However, the investment carries significant risks inherent to early-stage biotechnology. Verve currently operates with a negative Profit Margin of -176.0%, reflecting its intensive R&D phase and lack of commercialized products. While its Gross Margin is 100.0% due to the absence of cost of goods sold for commercial products, this highlights its pre-revenue status. The company's high Beta of 2.24 indicates substantial volatility, typical for a biotech firm with a pipeline-driven valuation. Key growth catalysts include positive clinical trial results for VERVE-101 and the ANGPTL3 program, regulatory milestones, and potential expansion into new indications or partnerships. Investors must closely monitor clinical progress and regulatory approvals, as these will be critical determinants of future valuation and commercial viability. The $994.04M market capitalization reflects market anticipation for its groundbreaking technology, but successful clinical translation remains paramount.

Based on FMP financials and quantitative analysis

VERV Key Highlights

• Market Capitalization: Verve Therapeutics maintains a market capitalization of $994.04M, reflecting investor valuation of its early-stage gene-editing pipeline and future potential in cardiovascular disease.
• Profit Margin: The company reported a Profit Margin of -176.0%, indicative of its significant research and development expenditures as a pre-commercial biotechnology firm.
• Gross Margin: Verve Therapeutics exhibits a Gross Margin of 100.0%, which is typical for a company in the clinical development phase with no commercialized products generating cost of goods sold.
• Employee Base: The company operates with a team of 274 employees, primarily focused on advancing its gene-editing programs and supporting research and development activities.
• Market Volatility (Beta): With a Beta of 2.24, Verve Therapeutics demonstrates higher volatility compared to the broader market, a characteristic often associated with biotechnology companies reliant on clinical trial outcomes.

Who Are VERV's Competitors?

VERV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VERV's Key Strengths?

• Pioneering gene-editing technology for cardiovascular diseases, offering potentially durable, single-course treatments.
• Strong intellectual property base through licenses for foundational Cas9 gene-editing technology.
• Strategic partnerships with key players like Beam Therapeutics and Acuitas Therapeutics, enhancing R&D capabilities.
• Focused pipeline with lead programs (VERVE-101, ANGPTL3) addressing significant unmet medical needs in lipid disorders.

What Are VERV's Weaknesses?

• Currently pre-revenue with a negative Profit Margin of -176.0%, indicating high R&D costs and reliance on external funding.
• High clinical and regulatory risk associated with novel gene-editing technologies, which are complex and subject to stringent review.
• Limited product diversification, with the company's valuation heavily dependent on the success of a few lead pipeline candidates.
• No commercialized products, requiring significant time and investment before potential market entry and profitability.

What Could Drive VERV Stock Higher?

• Clinical Trial Data for VERVE-101: Positive interim or full clinical trial results for VERVE-101, demonstrating favorable safety and efficacy profiles in human studies, would be a significant catalyst. Such data, expected in the mid-to-late 2020s, could validate Verve's gene-editing platform and de-risk its lead program, potentially accelerating its path towards later-stage development and regulatory submissions.
• Advancement of ANGPTL3 Program: Progress in the ANGPTL3 gene-editing program, including the initiation of human clinical trials or the release of robust preclinical data, would signal pipeline expansion and diversification. This program targets another key lipid pathway, and its successful advancement, anticipated in the late 2020s, could broaden Verve's therapeutic reach and market potential beyond PCSK9.
• Expansion of Strategic Partnerships: The announcement of new or expanded strategic collaborations with pharmaceutical companies or technology providers could provide non-dilutive funding, access to specialized expertise, and accelerate the development or commercialization of Verve's therapies. Such partnerships, continuously sought by biotech firms, could enhance Verve's resources and market reach throughout the late 2020s.
• Regulatory Milestones: Achievement of key regulatory milestones, such as Fast Track designation, Orphan Drug designation, or the successful submission of Investigational New Drug (IND) applications for new programs, would indicate regulatory alignment and progress. These milestones, expected as programs advance through the pipeline, are crucial for moving experimental therapies closer to patient access.

What Are the Key Risks for VERV?

• Negative return on equity (-36.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $43.9M recently.
• Clinical Trial Failure: The primary risk for Verve Therapeutics is the potential for its gene-editing candidates, particularly VERVE-101 and the ANGPTL3 program, to fail in clinical trials. This could manifest as insufficient efficacy, unacceptable safety profiles, or unexpected adverse events, leading to program termination and significant loss of investment.
• Regulatory Hurdles: Gene-editing therapies face stringent regulatory scrutiny due to their novel mechanism of action and potential for irreversible changes. Delays in regulatory approvals, additional data requirements, or outright non-approval by health authorities could significantly impede market entry and commercial viability.
• High Research and Development Costs: As a pre-revenue biotechnology company, Verve incurs substantial research and development expenses. Continued funding is critical, and any inability to secure additional capital through equity offerings or partnerships could jeopardize the advancement of its pipeline.
• Intellectual Property Challenges: The gene-editing landscape is complex and competitive, with numerous patents. Verve faces the ongoing risk of intellectual property disputes, patent infringements, or challenges to its licensed technologies, which could impact its freedom to operate or require costly litigation.
• Competition from Other Therapies: Despite its innovative approach, Verve faces competition from existing lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) and other emerging therapies, including gene therapies from competitors, that could offer similar or superior efficacy or safety profiles.

What Are the Growth Opportunities for VERV?

• Advancement of Lead Gene-Editing Programs: Verve's primary growth opportunity lies in the successful progression of its lead experimental therapies, VERVE-101 and the ANGPTL3 program, through clinical development. VERVE-101, targeting the PCSK9 gene for irreversible inactivation, addresses hypercholesterolemia, a condition affecting millions globally. Successful Phase 1/2 and subsequent clinical trials, demonstrating both safety and efficacy, would significantly de-risk the asset and unlock substantial market potential. The global market for dyslipidemia treatments is projected to reach tens of billions of dollars, and a single-course gene-editing therapy could capture a significant share by offering a durable alternative to chronic medication. Timelines for such advancements typically span several years, with key milestones expected in the mid-to-late 2020s.
• Expansion into Additional Cardiovascular Indications: Beyond its initial focus on PCSK9 and ANGPTL3, Verve has the opportunity to leverage its foundational gene-editing platform to address a broader spectrum of cardiovascular diseases. The underlying technology, capable of precisely editing genes in the liver, could be adapted to target other genetic drivers of heart disease, such as familial hypercholesterolemia or other lipid disorders. Identifying and initiating new preclinical and clinical programs for these indications would expand the company's total addressable market and diversify its pipeline. Each new indication represents a multi-billion dollar market opportunity, with initial exploratory work potentially beginning in the late 2020s.
• Strategic Partnerships and Licensing Deals: Verve's existing collaborations with Beam Therapeutics Inc. and Acuitas Therapeutics, Inc. demonstrate the value of its technology. Future growth can be catalyzed by forging additional strategic partnerships with larger pharmaceutical companies. These collaborations could provide non-dilutive funding, access to broader development and commercialization expertise, and accelerate market penetration for its gene-editing therapies. Such partnerships might involve co-development agreements, regional licensing, or technology platforms, potentially generating upfront payments, milestone payments, and royalties. The timeline for new partnerships is ongoing, driven by clinical progress and strategic alignment.
• Optimization and Expansion of Gene-Editing Technology: Continuous innovation in its core gene-editing technology, including improvements in delivery systems, specificity, and safety profiles, represents a significant growth driver. Enhancing the efficiency and applicability of its Cas9 gene-editing platform, potentially through next-generation editors or novel delivery vectors, could broaden the scope of treatable genetic conditions and improve therapeutic outcomes. Investing in R&D to refine these technologies ensures Verve remains at the cutting edge of genetic medicine. Advances in this area could lead to new intellectual property and competitive advantages, with ongoing research and development efforts throughout the late 2020s and beyond.
• Geographic Market Expansion and Regulatory Approvals: As Verve's therapies advance through clinical trials, securing regulatory approvals in major global markets beyond the US, such as Europe and Asia, will be crucial for maximizing commercial potential. Each regulatory approval represents a gateway to new patient populations and revenue streams. The global market for cardiovascular drugs is vast, and successful market entry in multiple key regions would significantly amplify the impact of its gene-editing treatments. This opportunity is contingent on successful clinical outcomes and navigating diverse regulatory landscapes, with initial market entries potentially occurring in the early 2030s following late-stage clinical development.

What Opportunities Does VERV Have?

• Expansion of its gene-editing platform to target additional cardiovascular diseases or other genetic disorders.
• Formation of new strategic collaborations or licensing agreements to accelerate development and commercialization efforts.
• Potential for significant market disruption if single-course gene-editing therapies prove safe and effective for chronic conditions.
• Advancements in gene-editing delivery systems and technologies that could improve efficacy and safety profiles.

What Threats Does VERV Face?

• Clinical trial failures or unexpected adverse events could significantly impact pipeline viability and investor confidence.
• Intense competition from other biotechnology and pharmaceutical companies developing novel cardiovascular treatments, including gene therapies.
• Stringent and evolving regulatory landscape for gene-editing therapies, potentially leading to delays or non-approvals.
• Patent challenges or expiration of key intellectual property could erode competitive advantages.

What Are VERV's Competitive Advantages?

• Proprietary Gene-Editing Technology: Holds licenses for foundational Cas9 gene-editing technology from The Broad Institute and Harvard College, providing a strong intellectual property position in this cutting-edge field.
• Targeted Therapeutic Approach: Focuses on single-course, irreversible gene inactivation in the liver for cardiovascular diseases, a highly specific and potentially durable treatment paradigm that differentiates it from conventional therapies.
• Strategic Partnerships: Collaborations with Beam Therapeutics Inc. for genetic medicines and Acuitas Therapeutics, Inc. for lipid nanoparticle delivery systems provide access to specialized expertise and technology, enhancing its development capabilities.
• First-Mover Advantage: As a pioneer in developing gene-editing therapies specifically for cardiovascular diseases, Verve aims to establish a leading position in this emerging therapeutic area.
• Scientific Expertise: Led by a team with deep scientific and clinical expertise in genetics, cardiology, and gene editing, enabling the complex R&D required for its innovative pipeline.

What Does VERV Do?

Verve Therapeutics, Inc. is a biotechnology company established in 2018, initially incorporated as Endcadia, Inc. before rebranding in January 2019. Headquartered in Boston, US, the firm is dedicated to developing innovative gene-editing treatments specifically for individuals afflicted with cardiovascular diseases, a leading cause of mortality globally. The company's core strategy revolves around creating single-course therapies designed to durably lower blood lipids by precisely editing specific genes within the liver. Verve's flagship experimental therapy, VERVE-101, exemplifies this approach. It is engineered as a singular gene-editing intervention intended to irreversibly inactivate the PCSK9 gene in the liver. This inactivation aims to reduce low-density lipoprotein cholesterol (LDL-C), a primary driver of atherosclerotic cardiovascular disease. Beyond VERVE-101, the company is actively advancing an ANGPTL3 program, which similarly seeks to permanently switch off the ANGPTL3 gene in the liver, targeting another pathway involved in lipid metabolism. To bolster its research and development efforts, Verve Therapeutics has cultivated several strategic collaborations. These include a significant collaboration and licensing pact with Beam Therapeutics Inc., a leader in precision genetic medicines. Additionally, Verve holds a development and option agreement with Acuitas Therapeutics, Inc., a company specializing in lipid nanoparticle (LNP) delivery systems crucial for gene-editing therapies. The foundational Cas9 gene-editing technology, central to Verve's platform, is licensed from prestigious institutions: The Broad Institute of MIT and Harvard and the President and Fellows of Harvard College. These partnerships provide Verve with access to cutting-edge technology and expertise, positioning it at the forefront of gene-editing innovation for cardiovascular health. The company operates with a team of 274 employees, all focused on bringing these potentially transformative therapies to patients.

What Products and Services Does VERV Offer?

• Develops single-course gene-editing medicines for cardiovascular diseases.
• Focuses on irreversibly inactivating specific genes in the liver to lower blood lipids.
• Advancing VERVE-101, an experimental therapy targeting the PCSK9 gene.
• Progressing an ANGPTL3 program aimed at permanently switching off the ANGPTL3 gene.
• Utilizes Cas9 gene-editing technology licensed from The Broad Institute and Harvard College.
• Engages in strategic partnerships, including with Beam Therapeutics Inc. and Acuitas Therapeutics, Inc., for technology and development.
• Conducts extensive research and development to bring novel genetic therapies from preclinical stages through clinical trials.
• Aims to provide durable therapeutic solutions for patients with chronic cardiovascular conditions.

How Does VERV Make Money?

• Research and Development Focus: Primarily operates as a research and development company, investing heavily in preclinical and clinical studies for its gene-editing pipeline.
• Partnerships and Licensing: Generates potential revenue through collaboration agreements and licensing pacts, such as those with Beam Therapeutics and Acuitas Therapeutics, which may include upfront payments, milestone payments, and future royalties.
• Future Product Sales: Anticipates generating substantial revenue from the eventual commercialization and sales of its proprietary gene-editing therapies, such as VERVE-101, upon successful regulatory approval.
• Intellectual Property: Builds value through the development and protection of its intellectual property, including patents related to gene-editing targets, technologies, and therapeutic applications.

What Industry Does VERV Operate In?

Verve Therapeutics operates within the highly innovative and rapidly evolving biotechnology industry, specifically focusing on gene-editing therapies for cardiovascular diseases. The broader biotechnology sector is characterized by intensive research and development, lengthy clinical trial processes, and significant regulatory hurdles, but also holds the potential for transformative medical breakthroughs. The cardiovascular disease market is immense, representing a leading cause of morbidity and mortality globally, with a continuous need for more effective and durable treatment options beyond traditional pharmaceuticals. Verve's niche in gene editing positions it at the forefront of a paradigm shift in medicine, moving from chronic symptom management to single-course, potentially curative interventions. The competitive landscape includes established pharmaceutical companies with existing cardiovascular drug portfolios, as well as other biotech firms exploring gene therapies, RNA interference, and small molecule inhibitors for lipid disorders. Verve differentiates itself by targeting irreversible genetic inactivation of specific genes like PCSK9 and ANGPTL3, aiming for a durable therapeutic effect. Success in this field requires not only scientific innovation but also robust clinical validation and strategic partnerships to navigate complex development pathways.

Who Are VERV's Key Customers?

• Patients with Cardiovascular Diseases: Individuals suffering from conditions like hypercholesterolemia and other lipid disorders that are amenable to gene-editing interventions.
• Healthcare Providers: Cardiologists, endocrinologists, and other specialists who would prescribe and administer Verve's gene-editing therapies.
• Healthcare Systems and Payers: Insurance companies, government health programs, and hospitals that would cover the costs and facilitate the delivery of these advanced treatments.
• Academic and Research Institutions: Potential collaborators for further research into gene-editing applications and cardiovascular biology.

Net sellingInsider Activity

The most recent 12 insider filings for Verve Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 4.5M shares disposed (about $43.9M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Verve Therapeutics, Inc.

Revenue for Verve Therapeutics, Inc. came in at $33.0M during Q1 2025, a 152.1% improvement versus the preceding quarter. The company recorded a net loss of $31.0M, with diluted EPS of $-0.35. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, VERV averaged $-0.53 in diluted EPS.

VERV Valuation & Market Position

With a $994.04M market cap, Verve Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, VERV's quantitative score of 71/100 is roughly in line with the peer average of 76/100.

ROE -36%Key Financial Metrics

Return on equity for Verve Therapeutics, Inc. stands at -36.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Verve Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.35 places it in the grey zone, a middle ground that warrants monitoring.

8/8 beatsEarnings Track Record

Verve Therapeutics, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 20.3% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Verve Therapeutics, Inc. revenue of about $16.1M for fiscal 2026, with EPS near $-3.11. The estimate reflects 6 contributing analysts.

Company Profile

Verve Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Sekar Kathiresan. VERV has traded publicly since 2021.

VERV Financials

VERV Latest News

VERV Analyst Consensus

VERV MoonshotScore

What Investors Ask About Verve Therapeutics, Inc. (VERV) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources